ERRATUM

Open Access



Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

Sotirios P. Fortis^{1†}, Michael Sofopoulos^{2†}, Nectaria N. Sotiriadou², Christoforos Haritos¹, Christoforos K. Vaxevanis¹, Eleftheria A. Anastasopoulou¹, Nicole Janssen³, Niki Arnogiannaki², Alexandros Ardavanis⁴, Graham Pawelec³, Sonia A. Perez^{1*†} and Constantin N. Baxevanis^{1†}

Erratum

After publication of this article [1], it was noticed that Table 3 contained errors introduced during the production process. The corrected Table 3 can be seen below and the original article has been updated to correct the errors.

Author details

¹Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece. ²Pathology Department, Saint Savas Cancer Hospital, Athens, Greece. ³Center for Medical Research, Eberhard-Karls Universität, Tübingen, Germany. ⁴First Medical Oncology Clinic, Saint Savas Cancer Hospital, Athens, Greece.

Received: 15 May 2017 Accepted: 15 May 2017 Published online: 30 May 2017

Reference

 Fortis, S. P., Sofopoulos, M., Sotiriadou, N. N., Haritos, C., Vaxevanis, C. K., Anastasopoulou, E. A., ... Baxevanis, C. N. Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. J Immunother Cancer. 2017, 5, 39. http://doi.org/10.1186/s40425-017-0240-7.

* Correspondence: perez@ciic.gr

[†]Equal contributors

¹Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece



© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

	DFS			OS		
	Hazard Ratio	Р	95.0% CI for HR (range)	Hazard Ratio	Р	95.0% CI for HR (range)
TNM stage ^b	2.180	0.009	1.219–3.898	3.937	0.006	1.494–10.371
Signatures ^b	1.560	0.138	0.866-2.810	2.085	0.091	0.889–4.890
Model before stepwise se	lection					
Age ^a	1.031	0.948	0.411-2.589	4.391	0.188	0.486-39.703
T status ^b	2.613	0.010	1.255–5.439	3.679	0.028	1.148–11.793
N stage ^b	1.222	0.512	0.671-2.225	1.125	0.815	0.420-3.010
Grade ^b	1.142	0.750	0.504-2.585	4.189	0.027	1.180–14.867
HER-2/neu	0.928	0.884	0.342-2.520	0.066	0.016	0.007-0.066
Hormone Receptors	0.277	0.004	0.277-0.669	0.618	0.007	0.046-0.621
Signatures ^b	2.063	0.041	1.031-4.126	4.850	0.014	1.374–17.122
Model after stepwise selec	ction					
T status ^b	2.999	0.001	1.602-5.615	3.522	0.005	1.477-8.398
Hormone Receptors	0.269	0.002	0.116-0.621	0.231	0.014	0.072-0.742
Signatures ^b	2.146	0.027	1.091–4.219	4.273	0.006	1.521-11.999

Table 3 Multivariate Cox proportional hazard analysis for DFS and OS of patients with non-mesastatic invasive breast cancer

^aAge under 50 and over 50 years old ^bAll categorical covariates were transformed into numeric codes as follows: T status (T1; 1, T2; 2, T3; 3), N stage (NO; 0, N1; 1, N2; 2, N3; 3), Grade (G1; 1, G2; 2, G3; 3), Signatures (FCIS; 1, Rest; 2, UCIS; 3) TNM stage (I; 1, II; 2, III; 3)